| Item Type | Name |
|
Concept
|
Acidosis
|
|
Concept
|
Administration, Intravesical
|
|
Concept
|
Administration, Oral
|
|
Concept
|
Aged
|
|
Concept
|
Aged, 80 and over
|
|
Concept
|
Alanine Transaminase
|
|
Concept
|
Analysis of Variance
|
|
Concept
|
Androgens
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Attitude of Health Personnel
|
|
Concept
|
BCG Vaccine
|
|
Concept
|
Benzamides
|
|
Concept
|
Biopsy
|
|
Concept
|
Blood Cells
|
|
Concept
|
Body Image
|
|
Concept
|
Carcinoma, Basal Cell
|
|
Concept
|
Carcinoma, Renal Cell
|
|
Concept
|
Cell Differentiation
|
|
Concept
|
Combined Modality Therapy
|
|
Concept
|
Drug Eruptions
|
|
Concept
|
DNA Repair
|
|
Concept
|
Dose-Response Relationship, Radiation
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Genetic Markers
|
|
Concept
|
Humans
|
|
Concept
|
Immunohistochemistry
|
|
Concept
|
Indazoles
|
|
Concept
|
Metformin
|
|
Concept
|
Methotrexate
|
|
Concept
|
Middle Aged
|
|
Concept
|
Obesity
|
|
Concept
|
Oregon
|
|
Concept
|
Patient Acceptance of Health Care
|
|
Concept
|
Phenylthiohydantoin
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
Safety
|
|
Concept
|
Thrombocytopenia
|
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
United States
|
|
Concept
|
Vinblastine
|
|
Concept
|
Blotting, Western
|
|
Concept
|
Antigens, Differentiation, Myelomonocytic
|
|
Concept
|
Cohort Studies
|
|
Concept
|
Down-Regulation
|
|
Concept
|
Cystectomy
|
|
Concept
|
Antigens, CD
|
|
Concept
|
Body Mass Index
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
Databases, Factual
|
|
Concept
|
Immunoglobulins, Intravenous
|
|
Concept
|
Chemotherapy, Adjuvant
|
|
Concept
|
Focus Groups
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Th2 Cells
|
|
Concept
|
Radiotherapy, Adjuvant
|
|
Concept
|
Immunoconjugates
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Delivery of Health Care, Integrated
|
|
Concept
|
Cell Lineage
|
|
Concept
|
Radiotherapy, Conformal
|
|
Concept
|
Neoadjuvant Therapy
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Genomics
|
|
Concept
|
MicroRNAs
|
|
Concept
|
Biomedical Research
|
|
Concept
|
Cell Proliferation
|
|
Concept
|
Radiotherapy, Intensity-Modulated
|
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 1
|
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 3
|
|
Concept
|
Xeroderma Pigmentosum Group D Protein
|
|
Concept
|
Basic Helix-Loop-Helix Transcription Factors
|
|
Concept
|
Biosynthetic Pathways
|
|
Concept
|
Hyperphosphatemia
|
|
Concept
|
Small Cell Lung Carcinoma
|
|
Concept
|
Drug Discovery
|
|
Concept
|
Young Adult
|
|
Concept
|
Patient Preference
|
|
Concept
|
Th17 Cells
|
|
Concept
|
Chemoradiotherapy
|
|
Concept
|
Transcriptome
|
|
Concept
|
B7-H1 Antigen
|
|
Concept
|
Clonal Evolution
|
|
Concept
|
Programmed Cell Death 1 Receptor
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Academic Article
|
Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience.
|
|
Academic Article
|
A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer.
|
|
Academic Article
|
Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.
|
|
Academic Article
|
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group.
|
|
Academic Article
|
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
|
|
Academic Article
|
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
|
|
Academic Article
|
Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma.
|
|
Academic Article
|
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
|
|
Academic Article
|
Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
|
|
Academic Article
|
Combination immunotherapy in genitourinary malignancies.
|
|
Academic Article
|
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
|
|
Academic Article
|
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
|
|
Academic Article
|
Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature.
|
|
Academic Article
|
Recent developments in the treatment of advanced bladder cancer.
|
|
Academic Article
|
Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.
|
|
Academic Article
|
First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.
|
|
Academic Article
|
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
|
|
Academic Article
|
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations.
|
|
Academic Article
|
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
|
|
Academic Article
|
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
|
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
|
Concept
|
Poly(ADP-ribose) Polymerase Inhibitors
|
|
Concept
|
Survivorship
|
|
Concept
|
Margins of Excision
|
|
Concept
|
Nectins
|
|
Concept
|
Aurora Kinase A
|
|
Academic Article
|
Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer.
|
|
Academic Article
|
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
|
|
Academic Article
|
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
|
|
Academic Article
|
Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome.
|
|
Academic Article
|
Understanding Psychosocial and Sexual Health Concerns Among Women With Bladder Cancer Undergoing Radical Cystectomy.
|
|
Academic Article
|
Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
|
|
Academic Article
|
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.
|
|
Academic Article
|
Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience.
|
|
Academic Article
|
Imaging urothelial bladder cancer: A VPAC PET targeted approach.
|
|
Academic Article
|
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?
|
|
Academic Article
|
Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma.
|
|
Academic Article
|
Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy.
|
|
Academic Article
|
Penile sarcomatoid urothelial carcinoma: A case report.
|
|
Academic Article
|
A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Gu?rin-exposed Non-muscle-invasive Bladder Cancer.
|
|
Academic Article
|
Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials.
|
|
Academic Article
|
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
|
|
Academic Article
|
Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context.
|
|
Academic Article
|
Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the?bladder.
|
|
Academic Article
|
Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature.
|
|
Academic Article
|
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
|
|
Academic Article
|
Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder.
|
|
Academic Article
|
Enhancing bladder cancer care through the multidisciplinary clinic approach.
|
|
Academic Article
|
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations.
|
|
Academic Article
|
The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
|
|
Academic Article
|
Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
|
|
Academic Article
|
PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers.
|
|
Academic Article
|
Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy.
|
|
Academic Article
|
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
|
|
Academic Article
|
Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience.
|
|
Academic Article
|
Racial Differences in Cutaneous Events Among Patients Receiving Enfortumab Vedotin.
|
|
Academic Article
|
Frontline immune checkpoint inhibitors in patients = 90 years with advanced urothelial cancer: a single center experience.
|
|
Academic Article
|
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis.
|
|
Academic Article
|
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
|
|
Academic Article
|
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
|
|
Academic Article
|
The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer.
|
|
Academic Article
|
Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cells.
|
|
Academic Article
|
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.
|